Briviact brivaracetam APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaNeurology
Launch2016-02-18
US LOE2031-02-01
Peak Sales Est$800M
Formulations[{"id":"briviact-oral","doses":"10mg, 25mg, 50mg, 75mg, 100mg","route":"PO","device":"Tablet/oral so
Companies
UCB (ORIGINATOR)100%
Mechanism: SV2A ligand
Expert: High-affinity ligand for synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and exhibiting antiepileptic activity through a novel mechanism.
Everyday: Binds to a protein in brain cells that helps control the release of brain chemicals, reducing seizures.
Targets: ["SV2A"]
Revenue History
PeriodRevenue ($M)
2024$580M
Q4 2024$155M
Programs (1)
IndicationStageKey StudyRegional Status
Focal onset seizuresAPPROVEDN01252, N01253, N01254[{"stage":"APPROVED","region":"US","approval_date":"2016-02-18"},{"stage":"APPRO
Notes
Brivaracetam, a next-generation anticonvulsant with high-affinity SV2A binding for partial-onset seizures. Designed as a more potent and selective follow-on to levetiracetam (Keppra) with improved tolerability.
Data from Supabase · Updated 2026-03-24